Amgen Inc. (NASDAQ:AMGN)‘s stock had its “hold” rating restated by research analysts at Deutsche Bank AG in a report issued on Wednesday. They currently have a $174.00 price target on the medical research company’s stock, up from their prior price target of $172.00. Deutsche Bank AG’s price objective would indicate a potential downside of 3.81% from the company’s current price.

Several other brokerages have also weighed in on AMGN. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Cann reaffirmed a “buy” rating and issued a $203.00 target price (up from $189.00) on shares of Amgen in a research report on Wednesday. Cowen and Company reissued an “outperform” rating and issued a $209.00 price objective on shares of Amgen in a research report on Saturday. Credit Suisse Group set a $177.00 price objective on Amgen and gave the company a “hold” rating in a research report on Friday, July 14th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $195.00 price objective on shares of Amgen in a research report on Monday, July 17th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have issued a buy rating and three have assigned a strong buy rating to the stock. Amgen has a consensus rating of “Buy” and an average target price of $185.94.

Shares of Amgen (NASDAQ AMGN) traded down 2.95% during midday trading on Wednesday, hitting $175.55. The stock had a trading volume of 2,902,534 shares. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21. The stock has a market cap of $129.10 billion, a P/E ratio of 16.67 and a beta of 1.36. The stock has a 50-day moving average price of $170.78 and a 200-day moving average price of $165.90.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the company posted $2.84 EPS. Equities analysts forecast that Amgen will post $12.48 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/07/26/amgens-amgn-hold-rating-reiterated-at-deutsche-bank-ag.html.

In other news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in AMGN. Integrated Wealth Management boosted its stake in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock valued at $141,000 after buying an additional 3 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the last quarter. Goelzer Investment Management Inc. boosted its stake in shares of Amgen by 0.3% in the second quarter. Goelzer Investment Management Inc. now owns 1,604 shares of the medical research company’s stock valued at $244,000 after buying an additional 5 shares during the last quarter. Capital Advisors Ltd. LLC boosted its stake in shares of Amgen by 0.5% in the third quarter. Capital Advisors Ltd. LLC now owns 1,083 shares of the medical research company’s stock valued at $181,000 after buying an additional 5 shares during the last quarter. Finally, Nadler Financial Group Inc. boosted its stake in shares of Amgen by 0.3% in the second quarter. Nadler Financial Group Inc. now owns 2,111 shares of the medical research company’s stock valued at $321,000 after buying an additional 6 shares during the last quarter. 78.87% of the stock is currently owned by institutional investors.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.